Acorda Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, ACOR, Acorda Therapeutics Inc, priceseries

Acorda Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
2.14
Close
2.19
High
2.24
Low
2.13
Previous Close
2.14
Daily Price Gain
0.05
YTD High
2.60
YTD High Date
Jan 4, 2022
YTD Low
1.61
YTD Low Date
Jan 28, 2022
YTD Price Change
-0.31
YTD Gain
-12.40%
52 Week High
6.36
52 Week High Date
Jul 23, 2021
52 Week Low
1.61
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-2.98
52 Week Gain
-57.64%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
117.00
Jan 17. 2017
123.96
9 Trading Days
5.95%
Link
LONG
Feb 14. 2017
143.10
Mar 14. 2017
166.38
19 Trading Days
16.27%
Link
LONG
Jun 8. 2017
97.20
Jul 18. 2017
119.55
27 Trading Days
23.00%
Link
LONG
Sep 29. 2017
141.90
Oct 9. 2017
150.82
6 Trading Days
6.29%
Link
LONG
Jan 9. 2018
139.50
Jan 30. 2018
159.74
14 Trading Days
14.51%
Link
LONG
May 25. 2018
145.20
Jun 21. 2018
181.48
18 Trading Days
24.98%
Link
LONG
Aug 10. 2018
161.40
Aug 29. 2018
171.87
13 Trading Days
6.49%
Link
LONG
Dec 31. 2018
93.48
Jan 14. 2019
99.09
9 Trading Days
6.01%
Link
LONG
Sep 9. 2019
18.90
Sep 17. 2019
20.19
6 Trading Days
6.83%
Link
LONG
Dec 20. 2019
10.68
Dec 31. 2019
12.13
6 Trading Days
13.62%
Link
LONG
Mar 25. 2020
5.96
Mar 30. 2020
6.40
3 Trading Days
7.40%
Link
LONG
Apr 6. 2020
5.58
Apr 7. 2020
5.88
1 Trading Days
5.38%
Link
LONG
Jul 21. 2020
4.90
Jul 23. 2020
5.15
2 Trading Days
5.13%
Link
LONG
Sep 25. 2020
3.69
Sep 28. 2020
4.04
1 Trading Days
9.35%
Link
LONG
Oct 2. 2020
3.36
Oct 16. 2020
4.01
10 Trading Days
19.38%
Link
LONG
Oct 19. 2020
4.14
Nov 4. 2020
5.62
12 Trading Days
35.86%
Link
LONG
Jan 12. 2021
4.24
Jan 28. 2021
6.66
11 Trading Days
57.05%
Link
LONG
Feb 2. 2021
6.97
Feb 17. 2021
7.42
10 Trading Days
6.44%
Link
LONG
Jun 11. 2021
3.85
Jun 29. 2021
4.83
12 Trading Days
25.34%
Link
LONG
Aug 20. 2021
3.88
Sep 7. 2021
4.21
11 Trading Days
8.41%
Link
Company Information
Stock Symbol
ACOR
Exchange
NasdaqGS
Company URL
http://www.acorda.com
Company Phone
914-347-4300
CEO
Ronald Cohen
Headquarters
New York
Business Address
420 SAW MILL RIVER ROAD, ARDSLEY, NY 10502
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001008848
About

Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders. The company's two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. Acorda Therapeutics was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinson's disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinson's disease; SYN120, which is in Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading